Clin Respir Med | Volume 2, Issue 1 | Review Article | Open Access
Milanese M1, Viegi G2, Sposato B3 and Dal Negro RW4*
1Azienda Sanitaria Locale 2, Italy
2Institutes of Biomedicine and Molecular Immunology, National Research Council, Italy
3Misericordia Hospital Grosseto, Italy
4National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology, Italy
*Correspondance to: Dal Negro RW
Fulltext PDFPrecision medicine aims to deliver treatments tailored to the individual patient with the most appropriate and the best management possible, and with a balance between patients’ outcomes and socio-economic savings. In this scenario, what is the role of respiratory function testing delivered by Lung Units within the different National Health Systems? In our personal view, we believe that respiratory function testing should be considered a pillar proceeding to Precision medicine. After underscoring the mandatory role of respiratory function testing for the diagnosis of a significant group of respiratory diseases (i.e. Asthma, COPD, IPF, OSAS), we describe its major contribute in the “phenotypic” recognition of treatable traits of airway obstructive disease. But we point out also that the selection of patients for advanced therapies (omalizumab, pirfenidone, nintedanib) or approaches (i.e. lung volume reduction, bronchial thermoplasty) strongly depends on data derived from Respiratory Function Testing. Finally, we highlight that new technologies or applications in respiratory pathophysiology are opening new horizons for a precision medicine approach.
Milanese M, Viegi G, Sposato B, Dal Negro RW. Respiratory Function Testing in the Era of Precision Medicine. Clin Respirat Med. 2020; 2(1): 1009.